Valuation: Arcellx, Inc.

Market Cap 6.75B 5.87B 5.46B 5.02B 9.47B 644B 9.62B 64.39B 25.27B 321B 25.36B 24.8B 1,076B P/E 2024
-38.3x
P/E 2025 -16x
Enterprise Value 6.28B 5.46B 5.08B 4.67B 8.81B 600B 8.95B 59.93B 23.52B 299B 23.6B 23.08B 1,001B EV / Sales 2024
33,125,319x
EV / Sales 2025 148,161,186x
Free-Float
88.44%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Arcellx, Inc.

1 day+0.03%
6 months+68.45%
Current year+76.49%
Current year 60.36
Extreme 60.355
115.13
1 year 60.36
Extreme 60.355
115.13
3 years 30.88
Extreme 30.88
115.13
5 years 6.04
Extreme 6.035
115.13
10 years 6.04
Extreme 6.035
115.13
Date Insider Type Main position Quantity % Market Cap.
4/28/26 Issuer sale

Director

28,644 0.0490%
2/27/26 Fiscal year

Chief Executive Officer

254,464 0.4401%
2/25/26 Fiscal year

Chief Financial Officer

31,749 0.0549%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-.--%+61.75%+236.66% 6.75B
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+411.96%+495.33% 39.87B
-1.16%+12.96%+28.81%+7.25% 38.68B
-1.88%-3.03%+5.69%+53.00% 35.13B
-1.74%+5.12%+14.44%+41.77% 29.79B
-0.21%-4.04%+36.40%+125.75% 16.11B
-2.85%-3.92% - - 16.08B
-0.64%+2.65%+3.40%+13.11% 13.61B
-1.19%-1.32%-1.73%-34.37% 12.62B
Average -1.35%+0.95%+62.11%+105.53% 25.72B
Weighted average by Cap. -1.55%+1.98%+79.28%+112.20%

Financials

2024 2025
Net sales 107.94 93.83 87.33 80.18 151.42 10.3K 153.77 1.03K 404.03 5.13K 405.36 396.46 17.2K 22.29 19.37 18.03 16.56 31.26 2.13K 31.75 212.55 83.42 1.06K 83.7 81.86 3.55K
Net income -107M -93.32M -86.86M -79.75M -151M -10.25B -153M -1.02B -402M -5.1B -403M -394M -17.11B -229M -199M -185M -170M -321M -21.85B -326M -2.18B -857M -10.88B -860M -841M -36.48B
Net Debt -572M -497M -462M -425M -802M -54.56B -814M -5.45B -2.14B -27.16B -2.15B -2.1B -91.08B -468M -407M -379M -348M -657M -44.69B -667M -4.46B -1.75B -22.25B -1.76B -1.72B -74.6B
Logo Arcellx, Inc.
Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Employees
209
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ACLX Stock